Literature DB >> 3112220

Genetic influence on the levels of circulating CD5 B lymphocytes.

T J Kipps, J H Vaughan.   

Abstract

By using sensitive two- and three-color immunofluorescence analyses, we readily detect CD5B cells (Leu 1 B cells) in the peripheral blood of normal adults. These circulating CD5 B lymphocytes coexpress B cell differentiation antigens CD20, CD21, CD19, sIgM and sIgD, and HLA-DR. Unlike CD5-negative B cells from most adults, however, these cells co-express CD11, a finding also noted for malignant CD5 B cells from several patients with CLL. Between normal volunteers, there exists heterogeneity in the proportion of PBL that co-express CD5 and B cell surface antigens, such cells representing between 0 and 6% of peripheral lymphocytes. Despite such heterogeneity between unrelated individuals, analyses of repeated blood samples from the same person reveal that the proportions of CD5 B lymphocytes are constant over time. Examination of blood samples from related family members, monozygotic twins, and triplets indicate that the relative proportion of circulating CD5 B cells may be genetically regulated. This is apparent even for monozygotic twins discordant for rheumatoid arthritis. Four sets of such twins are examined, each set having one individual with clinically active, seropositive rheumatoid arthritis and another without detectable rheumatoid factor or clinical pathology. Despite such noted differences, twins from each set share identical proportions of circulating CD5 B cells. In summary, our studies indicate that the level of CD5 B lymphocytes is a rather stable phenotypic trait that is under genetic control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112220

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Identification and analysis of a novel human surface CD5- B lymphocyte subset producing natural antibodies.

Authors:  M T Kasaian; H Ikematsu; P Casali
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

2.  Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes.

Authors:  T J Kipps; S F Duffy
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

3.  Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis.

Authors:  E W Schettino; A Cerutti; N Chiorazzi; P Casali
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

4.  B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  E Mix; T Olsson; J Correale; S Baig; V Kostulas; O Olsson; H Link
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

5.  Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.

Authors:  N Suzuki; T Sakane; E G Engleman
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

6.  In vitro IgM and IgM rheumatoid factor production in response to Staphylococcus aureus Cowan I and pokeweed mitogen: the contribution of CD5+ (Leu 1) B cells.

Authors:  J Karsh; R Goldstein; A I Lazarovits
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

7.  Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia.

Authors:  T J Kipps; E Tomhave; L F Pratt; S Duffy; P P Chen; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals.

Authors:  A M Stall; M C Fariñas; D M Tarlinton; P A Lalor; L A Herzenberg; S Strober; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

10.  Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis.

Authors:  Steven K Lundy; David A Fox
Journal:  Arthritis Res Ther       Date:  2009-08-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.